Evidence map›Paper›PMID 10981034›Full record

ReviewCurrent gastroenterology reports2000

Leptin: pathogenesis and treatment of morbid obesity.

A Kumar, N A Inverso, C D Still

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current gastroenterology reports, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

A KumarSection of Gastroenterology and Nutrition, Geisinger Medical Center, 100 North Academy Avenue, Danville, PA 17822, USA. akumar@psghs.edu
N A Inverso
C D Still

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leptin is a hormone produced primarily by the adipocytes. It works through different receptors and seems to provide information to the hypothalamus about the energy status of the body. Although leptin appears to exert its anti-obesity effect through its central action, the full spectrum of its action is yet to be determined. Most obese subjects in studies have high serum levels of leptin, suggesting that the major problem is leptin resistance rather than leptin deficiency. Consequently, these patients may not respond to exogenous leptin. Recent trials have indicated, however, that leptin may have therapeutic potential in leptin-deficient as well as leptin-resistant states.

Indexed as

AnimalsDiabetes Mellitus, Type 2Gene ExpressionHumansLeptinNeuropeptide YObesity, MorbidReceptors, Cell SurfaceReceptors, LeptinLEPR protein, humanLeptinNeuropeptide YReceptors, Cell SurfaceReceptors, Leptin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.